Devil's Club: Limited Evidence for Anti-Inflammatory Use
Devil's club (Oplopanax horridum) lacks sufficient evidence to recommend for anti-inflammatory purposes, and the available research shows no hypoglycemic effect despite traditional use for diabetes. 1
Evidence Quality and Findings
The research on devil's club is extremely limited, consisting only of small pilot studies with negative or inconclusive results:
Diabetes/Hypoglycemic Claims
- A pilot study monitoring blood glucose levels in one insulin-dependent diabetic, one newly diagnosed non-insulin-dependent diabetic, and two healthy adults found no hypoglycemic effect from devil's club tea 1
- Despite traditional use by Pacific Northwest Native tribes for diabetes, controlled data do not support this indication 1
Anti-Inflammatory Properties
- No clinical trials exist evaluating devil's club for inflammatory conditions or pain relief 1
- The evidence base is insufficient to make any recommendations regarding safety or efficacy for anti-inflammatory purposes
Important Distinction: Devil's Claw vs. Devil's Club
The literature contains substantial research on devil's claw (Harpagophytum procumbens), which is a completely different plant from devil's club:
Devil's Claw Evidence (Not Devil's Club)
- Devil's claw showed some efficacy for osteoarthritis pain in multiple trials, though methodological quality was generally poor 2
- Preparations containing at least 50 mg harpagoside daily may provide pain relief with lower adverse event risk than synthetic analgesics 3
- However, preclinical studies showed devil's claw was completely ineffective at reducing inflammation in standard animal models, even at doses 100 times the human dose 4
- Devil's claw failed to inhibit prostaglandin synthetase in vitro, indicating it lacks the anti-inflammatory mechanism of NSAIDs 4
Clinical Recommendation
For patients seeking herbal anti-inflammatory options, devil's club cannot be recommended due to absence of evidence. If considering herbal approaches for musculoskeletal pain:
- First-line pharmacologic treatment remains topical NSAIDs for localized pain, with favorable safety profiles compared to oral analgesics 5
- Oral NSAIDs (ibuprofen, naproxen) should be used at the lowest effective dose for limited duration when needed 6, 7
- Supplements and herbal interventions for inflammatory conditions are conditionally recommended against due to safety concerns with unregulated formulations 8
Key Safety Concerns with Herbal Products
- Lack of standardization and regulation creates unpredictable dosing and potential contamination 8
- Unknown drug interactions, particularly with anticoagulants, NSAIDs, and immunosuppressive medications 6, 9
- Risk of delaying proven effective treatments 8
Patients using or considering devil's club should be counseled about the lack of evidence and encouraged to discuss all supplements transparently with their healthcare providers to assess for potential interactions and ensure appropriate conventional treatment is not delayed. 8